[go: up one dir, main page]

HUP0202253A2 - Szelektív iGluR5-receptorantagonisták a migrén kezelésére - Google Patents

Szelektív iGluR5-receptorantagonisták a migrén kezelésére

Info

Publication number
HUP0202253A2
HUP0202253A2 HU0202253A HUP0202253A HUP0202253A2 HU P0202253 A2 HUP0202253 A2 HU P0202253A2 HU 0202253 A HU0202253 A HU 0202253A HU P0202253 A HUP0202253 A HU P0202253A HU P0202253 A2 HUP0202253 A2 HU P0202253A2
Authority
HU
Hungary
Prior art keywords
alkyl
treatment
migraine
receptor antagonists
selective
Prior art date
Application number
HU0202253A
Other languages
English (en)
Inventor
David Bleakman
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0202253A2 publication Critical patent/HUP0202253A2/hu
Publication of HUP0202253A3 publication Critical patent/HUP0202253A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya eljárás migrén kezelésére vagy megelőzésére, amiabból áll, hogy a kezelésre szoruló beteg szervezetébe szelektíviGLuR5 receptorantagonista hatásos mennyiségét juttatják. A találmánytárgya továbbá szelektív iGLuR5 receptorantagonistaként működő (A)általános képletű vegyületek, ahol R1 és R2 hidrogénatom, alkil-,alkenil-, aralkil-, cikloalkil-alkil-, dialkilamino-alkil-,pirrolidino-alkil-, piperidino-alkil-, morfolino-alkil-csoport, éssói, valamint az e vegyületeket tartalmazó gyógyszerkészítmények. Ó
HU0202253A 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine HUP0202253A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (2)

Publication Number Publication Date
HUP0202253A2 true HUP0202253A2 (hu) 2002-11-28
HUP0202253A3 HUP0202253A3 (en) 2003-12-29

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202253A HUP0202253A3 (en) 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine

Country Status (28)

Country Link
US (4) US6566370B1 (hu)
EP (1) EP1200073B1 (hu)
JP (1) JP4619595B2 (hu)
KR (1) KR20020024300A (hu)
CN (1) CN1230174C (hu)
AR (1) AR029373A1 (hu)
AU (1) AU773304B2 (hu)
BR (1) BR0012175A (hu)
CA (1) CA2378613C (hu)
CZ (1) CZ20014488A3 (hu)
DE (1) DE60032905T2 (hu)
DK (1) DK1200073T3 (hu)
DZ (1) DZ3209A1 (hu)
EA (1) EA004290B1 (hu)
ES (1) ES2278619T3 (hu)
HK (1) HK1047036A1 (hu)
HR (1) HRP20020013A2 (hu)
HU (1) HUP0202253A3 (hu)
IL (1) IL146697A0 (hu)
MX (1) MXPA01012726A (hu)
MY (1) MY133503A (hu)
NO (1) NO20016246L (hu)
NZ (1) NZ515616A (hu)
PE (1) PE20010299A1 (hu)
PT (1) PT1200073E (hu)
SK (1) SK112002A3 (hu)
TR (1) TR200200066T2 (hu)
WO (1) WO2001001972A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046173A1 (en) * 1999-12-22 2001-06-28 Eli Lilly And Company SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS
ES2306690T3 (es) * 2001-01-05 2008-11-16 Eli Lilly And Company Antagonistas de receptores de aminoacidos excitatorios.
EP1351952A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
IL156138A0 (en) * 2001-01-05 2003-12-23 Lilly Co Eli Excitatory amino acid receptor antagonists
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
DK1511741T3 (da) 2002-04-26 2013-01-21 Lilly Co Eli Esterderivater af en decahydroisoquinolin-3-carboxylsyre som analgetika
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
CN112105640B (zh) 2018-03-05 2025-03-04 詹森药业有限公司 检测神经退行性变的测定
GEP20257732B (en) 2019-11-08 2025-02-10 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
CA2285192A1 (en) * 1997-04-07 1998-10-15 Smriti Iyengar Pharmacological agents
ATE240299T1 (de) 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure

Also Published As

Publication number Publication date
HRP20020013A2 (en) 2003-08-31
CA2378613A1 (en) 2001-01-11
DE60032905D1 (de) 2007-02-22
JP2003503449A (ja) 2003-01-28
HK1047036A1 (zh) 2003-02-07
IL146697A0 (en) 2002-07-25
KR20020024300A (ko) 2002-03-29
NO20016246D0 (no) 2001-12-19
MXPA01012726A (es) 2002-07-02
US6855823B2 (en) 2005-02-15
DZ3209A1 (fr) 2001-01-11
CA2378613C (en) 2007-10-02
BR0012175A (pt) 2002-03-05
EA004290B1 (ru) 2004-02-26
PE20010299A1 (es) 2001-03-07
JP4619595B2 (ja) 2011-01-26
PT1200073E (pt) 2007-03-30
US20030199546A1 (en) 2003-10-23
CN1359289A (zh) 2002-07-17
EA200200132A1 (ru) 2002-06-27
SK112002A3 (en) 2003-05-02
WO2001001972A3 (en) 2001-12-06
US7157582B2 (en) 2007-01-02
NO20016246L (no) 2002-03-04
CN1230174C (zh) 2005-12-07
US6759418B2 (en) 2004-07-06
WO2001001972A2 (en) 2001-01-11
ES2278619T3 (es) 2007-08-16
DE60032905T2 (de) 2007-10-18
NZ515616A (en) 2004-05-28
AR029373A1 (es) 2003-06-25
HUP0202253A3 (en) 2003-12-29
DK1200073T3 (da) 2007-05-07
TR200200066T2 (tr) 2002-04-22
US6566370B1 (en) 2003-05-20
CZ20014488A3 (cs) 2003-01-15
EP1200073B1 (en) 2007-01-10
MY133503A (en) 2007-11-30
AU773304B2 (en) 2004-05-20
US20040192722A1 (en) 2004-09-30
AU5873200A (en) 2001-01-22
US20050159445A1 (en) 2005-07-21
EP1200073A2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
HUP9800417A2 (hu) 5-Szubsztituált-3-(1,2,3,6-tetrahidro-piridin-4-il)-1H-indolok és 5-szubsztituált-3-(piridin-4-il)-1H-indolok, alkalmazásuk mint új 5-HT agonisták, a vegyületeket tartalmazó gyógyszerkészítmények
JO2371B1 (en) 4-phenyl-pyridine derivatives
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
BR0211305A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
MXPA05012247A (es) Derivados de bencimidazol nuevos.
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
DE60322680D1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
HUP0003836A2 (hu) Lazofoxifent tartalmazó gyógyszerkészítmények
SE0002729D0 (sv) Novel compound form
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees